share_log

Vertex Pharmaceuticals | SC TO-T/A: Third party tender offer statement (Amendment)

Vertex Pharmaceuticals | SC TO-T/A: Third party tender offer statement (Amendment)

福泰製藥 | SC TO-T/A：發行招標公告
美股sec公告 ·  05/08 20:58
牛牛AI助理已提取核心訊息
Vertex Pharmaceuticals Incorporated, through its wholly owned subsidiary Adams Merger Sub, Inc., has announced a tender offer to acquire all issued and outstanding shares of Alpine Immune Sciences, Inc. at a price of $65.00 per share in cash. The offer, detailed in an amendment to the Schedule TO filed with the SEC on April 22, 2024, is set to expire at 11:59 p.m. ET on May 17, 2024, unless extended. The amendment supplements previous disclosures, including the expected filing of Premerger Notification and Report Forms under the HSR Act by April 24, 2024, and provides additional information on the background of the offer and regulatory approvals. The offer's terms and conditions, including the potential extension of the expiration time, are outlined in the Offer to Purchase. Vertex has also filed related materials with the SEC, including a press release and excerpts from their Q1 earnings call on May 6, 2024.
Vertex Pharmaceuticals Incorporated, through its wholly owned subsidiary Adams Merger Sub, Inc., has announced a tender offer to acquire all issued and outstanding shares of Alpine Immune Sciences, Inc. at a price of $65.00 per share in cash. The offer, detailed in an amendment to the Schedule TO filed with the SEC on April 22, 2024, is set to expire at 11:59 p.m. ET on May 17, 2024, unless extended. The amendment supplements previous disclosures, including the expected filing of Premerger Notification and Report Forms under the HSR Act by April 24, 2024, and provides additional information on the background of the offer and regulatory approvals. The offer's terms and conditions, including the potential extension of the expiration time, are outlined in the Offer to Purchase. Vertex has also filed related materials with the SEC, including a press release and excerpts from their Q1 earnings call on May 6, 2024.
Vertex Pharmicals Incorporated通過其全資子公司Adams Merger Sub, Inc. 宣佈要約以每股65.00美元的現金價格收購Alpine Immune Sciences, Inc.的所有已發行和流通股份。該提議將在2024年4月22日向美國證券交易委員會提交的附表TO修正案中詳細說明，除非延期，否則將於美國東部時間2024年5月17日晚上 11:59 到期。該修正案補充了先前的披露，包括預計在2024年4月24日之前根據HSR法案提交合並前通知和報告表，並提供了有關要約背景和監管部門批准的更多信息。購買要約中概述了該優惠的條款和條件，包括可能的到期時間延長。Vertex還向美國證券交易委員會提交了相關材料，包括新聞稿和2024年5月6日第一季度業績電話會議的摘錄。
Vertex Pharmicals Incorporated通過其全資子公司Adams Merger Sub, Inc. 宣佈要約以每股65.00美元的現金價格收購Alpine Immune Sciences, Inc.的所有已發行和流通股份。該提議將在2024年4月22日向美國證券交易委員會提交的附表TO修正案中詳細說明，除非延期，否則將於美國東部時間2024年5月17日晚上 11:59 到期。該修正案補充了先前的披露，包括預計在2024年4月24日之前根據HSR法案提交合並前通知和報告表，並提供了有關要約背景和監管部門批准的更多信息。購買要約中概述了該優惠的條款和條件，包括可能的到期時間延長。Vertex還向美國證券交易委員會提交了相關材料，包括新聞稿和2024年5月6日第一季度業績電話會議的摘錄。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。